Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-25T13:49:37.035Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of Dyslipidaemia Risk among Patients Treated with Aripiprazole: Meta Analysis of Placebo- and Olanzapine-controlled Studies

Published online by Cambridge University Press:  16 April 2020

H. Peyro-Saint-Paul ,
J.-Y. Loze ,
S. Kaplita ,
J. Han ,
R.A. Baker ,
R. Cahn  and
R. Owen
H. Peyro-Saint-Paul
Affiliation:
Bristol-Myers Squibb, Paris, France
J.-Y. Loze
Affiliation:
Otsuka Pharmaceutical France, Paris, France
S. Kaplita
Affiliation:
Bristol-Myers Squibb, Wallingford, Princeton, USA
J. Han
Affiliation:
Bristol-Myers Squibb, Wallingford, Princeton, USA
R.A. Baker
Affiliation:
Bristol-Myers Squibb, Princeton, USA
R. Cahn
Affiliation:
Bristol-Myers Squibb, Paris, France
R. Owen
Affiliation:
Bristol-Myers Squibb, Wallingford, Princeton, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims:

To evaluate dyslipidaemia risk among patients with schizophrenia treated with aripiprazole or olanzapine.

Methods:

Pooled analysis of the aripiprazole clinical database, including studies of ≥7 days with at least an oral aripiprazole monotherapy arm. Mean changes from baseline to endpoint and shifts from normal to abnormal lipid levels were calculated.

Results:

Seventeen placebo- and five olanzapine-controlled studies (3 weeks->3 years) of adult patients (≥18 years) were included. Mean changes (LOCF) in lipids were similar between aripiprazole and placebo for all lipid parameters; aripiprazole showed significant improvements versus olanzapine (p≤0.01). the incidence (OC) of switching to abnormal lipid levels from baseline normal was similar between placebo and aripiprazole, and significantly lower with aripiprazole than olanzapine for most measures.

Conclusion:

Despite limitations inherent to pooled analyses, these findings lend further support to the differential profile of atypicals, with aripiprazole showing effects on lipids comparable with placebo.

Type
P03-19
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E1018
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.